Fore Capital LLC Boosts Stock Holdings in Precigen, Inc. (NASDAQ:PGEN)

Fore Capital LLC lifted its stake in Precigen, Inc. (NASDAQ:PGEN) by 27.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 391,811 shares of the biotechnology company’s stock after purchasing an additional 85,000 shares during the period. Fore Capital LLC owned about 0.13% of Precigen worth $439,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of PGEN. Stoneridge Investment Partners LLC lifted its position in shares of Precigen by 21.3% during the 4th quarter. Stoneridge Investment Partners LLC now owns 68,681 shares of the biotechnology company’s stock worth $77,000 after purchasing an additional 12,063 shares during the last quarter. SG Americas Securities LLC increased its holdings in Precigen by 27.9% in the fourth quarter. SG Americas Securities LLC now owns 57,641 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 12,578 shares during the last quarter. Rhumbline Advisers raised its stake in Precigen by 7.3% in the fourth quarter. Rhumbline Advisers now owns 197,134 shares of the biotechnology company’s stock valued at $221,000 after buying an additional 13,338 shares in the last quarter. Stifel Financial Corp lifted its holdings in Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after buying an additional 15,680 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Precigen by 1.0% during the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after acquiring an additional 29,253 shares in the last quarter. 33.51% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. JMP Securities reissued a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a report on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, Precigen has an average rating of “Hold” and a consensus price target of $7.00.

Precigen Stock Performance

PGEN opened at $1.78 on Thursday. Precigen, Inc. has a one year low of $0.65 and a one year high of $2.17. The stock has a market capitalization of $521.31 million, a P/E ratio of -3.24 and a beta of 1.57. The business’s 50-day simple moving average is $1.53 and its 200-day simple moving average is $1.12.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.